secwatch / observer
8-K filed May 15, 2026, 4:03 PM ET ticker NRIX CIK 0001549595
other confidence high sentiment neutral materiality 0.15

Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved

Nurix Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2026-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-15
Exact text from the filing
Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 63,592,948 16,334,570 3,819,495 Roger Dansey, M.D. 79,607,489 320,029 3,819,495 Paul M. Silva 59,298,612 20,628,906 3,819,495
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2026 at the 2026-05-15 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-15
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 83,555,977 166,391 24,645 —
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2026-05-15 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-15
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 72,458,920 6,895,394 573,204 3,819,495
View on SEC.gov

Browse all shareholder votes →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001549595-26-000028
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.